- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - AstraZeneca divests hypertension medicines
AnnouncementREG - AstraZeneca PLC - Brilinta met primary endpoint in stroke trial
AnnouncementREG - AstraZeneca PLC - Enhertu Phase II trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - AstraZeneca to recover brazikumab (MEDI2070)
AnnouncementREG - AstraZeneca PLC - FDA grants Lynparza Priority Review for PROfound
AnnouncementREG - AstraZeneca PLC - Imfinzi, tremelimumab granted ODD in liver cancer
AnnouncementREG - JPMorgan Elect PLC JPMorgan Elect-JPEI JPMorgan Elect PLC . - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Update on Epanova Phase III STRENGTH trial
AnnouncementREG - AstraZeneca PLC - Lynparza granted FDA Priority Review for PAOLA-1
AnnouncementREG - Law Debenture Corp - Net Asset Value and Portfolio Update
AnnouncementREG - AstraZeneca PLC - Lokelma approved in China for hyperkalaemia
AnnouncementREG - AstraZeneca PLC - Farxiga granted FDA heart failure Priority Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - US FDA approved Lynparza for pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Enhertu (trastuzumab deruxtecan) approved in US
AnnouncementREG - AstraZeneca PLC - Triple-combination approved in China for COPD
AnnouncementREG - AstraZeneca PLC - AstraZeneca divests rights to Arimidex and Casodex
AnnouncementREG - AstraZeneca PLC - FDA panel backs Lynparza use for pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Seroquel rights agreement complete: Europe, Russia
Announcement